Longevity & Life Extension

APCO has launched a new formula of Mylife100A to cater to the Longevity trend, focusing on cellular health restoration and reducing the risk of dementia. The company plans to publish its research in an international academic journal by September. It will expand its customer base through BIM Advisor and is preparing to export to South Africa via partner INFINITUM GLOBAL HEALTH, with an initial order of 1,500,000 bottles in the first year. For the second quarter of 2026, the company reported total revenue of 44.25 million baht and net profit of 11.06 million baht. In the first half of the year, total revenue was 93.81 million baht and net profit was 28.95 million baht.

The Trade Policy and Strategy Office revealed that health care and anti-aging trends will push global consumer spending on medical goods and services to as high as 6.7 trillion US dollars by 2040, more than doubling compared with the past 15 years. In 2025, Thailand's retail value in the herbal product group was 1.3575 billion US dollars, ranking 11th in the world, and is expected to reach 1.8364 billion US dollars by 2030. Consumers are willing to pay at least 20 percent more if products have scientific test results to support them. The Trade Policy and Strategy Office proposed four urgent strategies: upgrading agricultural extracts to the medical level, penetrating everyday products and personalized nutrition, integrating technology for personalized health care, and linking the service ecosystem with health tourism under the Agri-Wellness Synergy concept to transform Thailand's agricultural sector into a health economy.

Abacus Global Management reported second quarter 2026 results that exceeded its own guidance, with total revenue of $73.0 million, up 30% year over year, and adjusted net income of $27.1 million, above the high end of its $24 million to $26 million forecast. Adjusted EPS was $0.28, up 22% from $0.23 a year earlier, and adjusted EBITDA rose 27% to $39.9 million. The company's Life Solutions segment drove growth with revenue of $65.4 million, a 38.3% increase, while longevity fund inflows reached $544.2 million in the first half, surpassing its $500 million target. Management provided third quarter guidance of $26 million to $28 million in adjusted net income and reiterated full-year adjusted net income of $100 million to $106 million. The company also announced the launch of its first registered interval fund, the ABX Longevity Growth and Income Fund, and a $53 million minority investment in Manning & Napier.

Business Alignment Public Company Limited, or BIZ, reported second-quarter 2026 net profit of 85.18 million baht, up 87.75 percent from 45.37 million baht in the same period last year. Total revenue reached 542.57 million baht, a 29.51 percent increase from 418.94 million baht, driven mainly by the delivery of radiation therapy machines and medical equipment according to plan. CEO Sompong Chuenkittiyanont said the company will press ahead with expanding BIZGENES, a personalized DNA analysis platform, to capture the trend of preventive and personalized healthcare, while broadening service channels across hospitals, clinics, and general consumers. The company also plans to bid for new projects and negotiate with partners to support future projects, expressing confidence that full-year 2026 performance will grow as targeted, backed by its order backlog and rising after-sales maintenance revenue.

Medeze Group Public Company Limited, or MEDEZE, has signed a memorandum of understanding with Bangkok Hospital Udon to develop innovative medical and holistic healthcare services. The collaboration covers personal stem cell storage, hair root cell storage, immune potential testing, as well as the promotion of anti-aging medicine and precision medicine at Bangkok Hospital Udon in Udon Thani province. MEDEZE is a leader in stem cell banking with internationally recognized standards and is the first in Thailand to achieve cell bank accreditation.

Merz Aesthetics and the National Nanotechnology Center under NSTDA have signed a research collaboration on Aesthetic Longevity to elevate Thailand's beauty industry into a global hub. The goal is to transition from being a user of foreign innovations to a standard-setter and knowledge creator, supporting Thailand's health economy market valued at 1.4 trillion baht under the Thailand Global Health Hub 2025 to 2034 strategy. This partnership will leverage Nanotec's cellular-level research platforms, such as telomere analysis and epigenetic clock, together with Merz's technologies to generate scientific evidence that meets the needs of modern consumers who seek in-depth information before deciding on beauty services. Both parties view evidence-driven approaches as the key to market competition, enabling physicians to plan personalized treatments with greater precision and safety.

The global anti-aging supplements market is projected to reach USD 10.65 billion by 2035, growing at a compound annual growth rate of 7.88 percent from 2026 to 2035, according to a new report by SNS Insider. The market was valued at USD 5.00 billion in 2025. North America led with approximately 37 percent of global revenue in 2025, while the Asia Pacific region is expected to record the fastest growth at an 8.39 percent CAGR. The collagen segment held the largest ingredient share at about 69.22 percent in 2025, and the capsules and tablets formulation segment dominated due to convenience and precise dosage.

The Animal Longevity Summit has announced its inaugural two-day scientific conference, taking place October 1–2, 2026, in Toronto. The event will bring together leading experts in geroscience, veterinary medicine, biotechnology, and aging research to explore how the biology of aging can be measured, slowed, and translated into longer, healthier lives, beginning with animals. The summit arrives as landmark initiatives such as the Dog Aging Project and a growing number of veterinary clinical trials generate the first large-scale datasets on interventions to improve healthspan and longevity in companion animals. The conference program will feature eight scientific tracks covering canine longevity, comparative biology of aging, biomarkers, longevity interventions, veterinary geroscience, cross-species translation to human health, and emerging research from early-career scientists. The inaugural speaker lineup includes Dr. Matt Kaeberlein of the Dog Aging Project, Dr. Vera Gorbunova of the University of Rochester, Dr. Aubrey de Grey of the LEV Foundation, Dr. Varun Dwaraka of TruDiagnostic, Liz Parrish of BioViva, and Dr. Raghav Sehgal of Yale, with additional speakers to be announced. Industry participation is also expected, with Genflow Biosciences confirming it will present new findings from its SLAB study investigating gene therapy in aged beagles.

Serotonin Centers has opened a new location in Del Mar, marking the brand’s entry into the greater San Diego market. The center will serve communities including Del Mar, La Jolla, Solana Beach, Carmel Valley, Rancho Santa Fe, and Encinitas, offering physician-led services such as hormone optimization, medical weight loss, peptide therapy, hyperbaric oxygen therapy, and red light therapy. The location is owned and operated by Anazosis, LLC, and represents its first Serotonin Centers franchise. Founder and CEO Eric Casaburi cited San Diego’s health-conscious and performance-driven population as a natural fit for the company’s comprehensive longevity platform. The opening is part of Serotonin Centers’ national expansion strategy targeting high-growth markets with rising demand for medically guided wellness services.

BDMS Wellness Clinic, a subsidiary of Bangkok Dusit Medical Services Public Company Limited, or BDMS, has launched the Longevity Card, a personalized health care card valued at 1 million baht, to penetrate the luxury wellness market and elevate Thailand as a global health hub. Members will receive continuous care from a team of doctors and multidisciplinary professionals throughout one year, covering health monitoring programs, early-stage cancer and Alzheimer's risk screening, cellular and genetic analysis, as well as dental and skincare services. The card is available by invitation only with a limited number accepted each year, and is linked to benefits from a network of leading lifestyle and travel partners. Dr. Tanupol Virunhagarun, President of the BDMS Wellness Group Executive Committee, stated that the organization will continue to develop preventive health care technology to drive Thailand toward becoming a sustainable global health and wellness destination.

The biotechnology industry for life extension is attracting funds from global billionaires. One key technology is Senolytics, the development of drugs that destroy zombie cells, which are a cause of degenerative diseases. From an investment perspective, there are two interesting groups of listed companies. The first is Unity Biotechnology, a pioneer in developing localized Senolytic drugs, such as treatments for age-related macular degeneration, with strengths in intellectual property and a network of world-class researchers. The second is ChromaDex Corporation, which holds patents and manufactures NAD+ precursors under a business model of wholesale and direct-to-consumer sales, generating stable recurring revenue. Investing in this theme should therefore diversify risk between high-risk pioneers and cash-flow-generating infrastructure players.

Business Alignment Public Company Limited, or BIZ, is aggressively expanding its BIZGENES personalized DNA testing service for preventive health planning in the second half of the year, responding to the trend of healthy longevity. At the same time, the company is closely watching for clarity on the fiscal 2027 budget, which is expected to take effect from October onward, to support bidding for new medical equipment projects. Meanwhile, the Eastern Region Cancer Hospital in Chonburi Province, or Cancer Alliance Sriracha Hospital, has adjusted its strategy by focusing on adding supplementary services and targeting more self-paying patients to cope with intensifying competition from the rise of specialized centers in nearby areas. Chief Executive Officer Sompong Chuenkittiyanont revealed that the company remains confident in double-digit revenue growth this year, with a current backlog valued at approximately 1.5 billion baht, which will be gradually recognized as revenue according to plan.

First Choice Healthcare Solutions and Westin Acquisition Corp have entered into a definitive business combination agreement that values First Choice at a pro forma enterprise value of approximately $650 million. The transaction will accelerate First Choice's strategic rebrand to Wellgevity 360, a next-generation healthcare and wellness platform focused on longevity, preventative care, and personalized, biology-driven treatment solutions. Westin, a special purpose acquisition company listed on Nasdaq, will domesticate from the Cayman Islands to Nevada and continue as Wellgevity 360, with First Choice becoming a wholly owned subsidiary. The combined company is expected to trade on Nasdaq, and the deal is anticipated to close in the fourth quarter of 2026, subject to customary approvals and closing conditions. First Choice delivers clinician-led, whole-person care through functional health, longevity, and regenerative medicine clinics, targeting the fast-growing U.S. wellness economy, which the Global Wellness Institute values at $2.1 trillion with an annual growth rate of 7.9% from 2019 to 2024.

NOVI Health has been named a wellness partner for Visa Infinite's reimagined premium ecosystem across Asia Pacific, marking the first time preventative healthcare joins travel, dining and lifestyle as a defining pillar of the region's exclusive card programme. The Singapore-based longevity and metabolic health company will provide Visa Infinite members with access to its evidence-based approach to metabolic health, weight management and longevity, combining physician-led care, dedicated health coaching and proprietary technology. The partnership reflects a broader shift in the luxury landscape where healthspan and vitality are becoming new markers of premium living, according to NOVI Health co-founders Dr Sue-Anne Toh and Dr Kyle Tan. The announcement comes as NOVI Health accelerates its regional expansion, scaling its longevity programmes and exploring new markets beyond Singapore.

MDLifespan has opened a new location in Southlake, Texas, expanding access to its physician-led Advanced Serial Therapeutic Plasma Exchange protocols across the Dallas-Fort Worth region. The facility is located inside Dynamic Life Health Center at 190 S Peytonville Ave #120, Southlake, Texas 76092. To mark the opening, MDLifespan will host free educational webinars for patients and physicians on August 7, 2026, covering environmental toxins, chronic inflammation, and the science behind Advanced Serial TPE. The company, founded by Dr. Paul Savage, positions itself as the first nationwide medical group focused on removing environmental toxins and reversing chronic inflammation through personalized, serial plasma exchange procedures.

AEON, a leading longevity clinic in the region, has welcomed the establishment of the Dubai Longevity Authority, calling it a significant milestone for healthcare innovation. The new authority reinforces Dubai's commitment to preventive healthcare, healthy ageing, and longevity science under the D33 Agenda. AEON combines advanced diagnostics with personalized regenerative therapies to help clients maintain physical and cognitive function into later years. Dr. Jaffer Khan, Founder and CEO of AEON Clinic, said the authority reflects Dubai's ambition to shape the future of healthcare and that AEON is proud to support this vision by translating longevity science into clinical care.

Americans now believe they need $1.46 million to retire comfortably, a 15% jump from $1.26 million a year ago, according to Northwestern Mutual’s 2026 Planning & Progress Study. The figure matches the 2024 record high, while a separate BlackRock survey of 1,000 registered voters pegged the target at $2.1 million. Median retirement savings for Americans aged 55 to 64 sits at just $185,000, roughly 13% of the $1.46 million target, and 48% fear outliving their money. Northwestern Mutual’s chief field officer John Roberts cited persistent inflation, longer lifespans, Social Security uncertainty, and AI-related career worries as factors driving the higher target. A 20-year-old saving $385 a month at a 7% annual return would reach $1.46 million by age 65, illustrating the power of early compounding.

Several biotechs have landed sizable funding rounds even as investors remain selective. Ollin Biosciences announced a $330 million series B round co-led by TCGX and Arch Venture Partners to advance its next-generation VEGF/Ang2 bispecific antibody OLN324 for diabetic macular edema and wet age-related macular degeneration. Beeline Medicines, a Bristol Myers Squibb spinout backed by Bain Capital, emerged from stealth with $300 million to develop five in-licensed immunology drugs, including the phase 2 lupus pill afimetoran. New Limit closed a $435 million series C round backed by Founders Fund and Lilly Ventures, reaching an estimated $3.1 billion valuation, and plans to begin clinical trials next year for its epigenetic reprogramming therapy targeting liver aging.

Life Extension has introduced two new NMN (nicotinamide mononucleotide) formulas designed to increase NAD+ levels, a coenzyme that declines with age and is vital for cellular energy. The products are NAD+ Cell Support NMN Nicotinamide Mononucleotide, a stand-alone NMN supplement, and Optimized NAD+ NMN Nicotinamide Mononucleotide with Resveratrol Elite™, which combines NMN with a highly bioavailable form of resveratrol. Research scientist Kristen Dominguez, PhD, noted that NMN is a direct precursor to NAD+ with clinical data showing it helps increase NAD+ levels in the bloodstream. The resveratrol in the combined formula uses fenugreek seed fibers to achieve 10 times greater bioavailability than traditional resveratrol, offering additional healthy aging benefits. Both formulas are available in 30- and 90-count vegetarian capsules and are non-GMO and gluten-free.

Dr. Austin Harris, MD, founder of NeuroRelief Ketamine & Infusion Therapy, has announced the availability of NAD+ IV infusion therapy at the Sherman Oaks clinic. The therapy delivers nicotinamide adenine dinucleotide intravenously to support cellular energy production, mitochondrial function, and cognitive wellness. Treatments are administered under direct medical oversight with individualized dosing, targeting patients with fatigue, brain fog, stress-related exhaustion, or those seeking general vitality optimization. Dr. Harris stated the approach focuses on supporting patients at the cellular level for improvements in energy, cognition, and overall well-being.